Gp120 activates children's brain endothelial cells via CD4

M F Stins1, Y Shen, S H Huang

  • 1Division of Infectious Diseases, Childrens Hospital Los Angeles, California, USA.

Journal of Neurovirology
|August 23, 2001
PubMed

Insights

HIV-1 infection in children can cause encephalopathy. The study shows gp120 activates brain endothelial cells via CD4, potentially contributing to this condition.

Area of Science:

  • Neuroscience
  • Immunology
  • Virology

Background:

  • Human Immunodeficiency Virus type 1 (HIV-1) infection commonly leads to encephalopathy in children, a serious neurological complication.
  • The precise mechanisms driving HIV-1 encephalopathy pathogenesis remain incompletely understood.

Purpose of the Study:

  • To investigate the role of gp120, an HIV-1 envelope protein, in activating pediatric human brain microvascular endothelial cells (HBMEC).
  • To explore the potential involvement of CD4 receptors in gp120-mediated endothelial cell activation and subsequent immune cell migration.

Main Methods:

  • Primary pediatric HBMEC were cultured and exposed to gp120.
  • Expression of adhesion molecules (ICAM-1, VCAM-1) and secretion of IL-6 were measured.
  • Monocyte transmigration assays were performed across HBMEC monolayers.
  • CD4 expression on HBMEC and brain microvessels was assessed using immunofluorescence on cryosections.
  • The effect of anti-gp120 and anti-CD4 antibodies on monocyte migration was evaluated.

Main Results:

  • Gp120 significantly upregulated ICAM-1 and VCAM-1 expression on pediatric HBMEC.
  • Gp120 increased IL-6 secretion and enhanced monocyte transmigration across HBMEC monolayers.
  • CD4 was detected on isolated HBMEC and brain microvessels from children.
  • Monocyte migration induced by gp120 was significantly inhibited by both anti-gp120 and anti-CD4 antibodies.

Conclusions:

  • This study provides the first evidence that gp120 activates pediatric HBMEC through CD4-mediated signaling.
  • Gp120-induced activation of HBMEC and subsequent monocyte migration may be a key mechanism contributing to the development of HIV-1 encephalopathy in children.
  • Targeting the gp120-CD4 interaction could offer a therapeutic strategy for preventing or mitigating HIV-1-associated neurological damage in pediatric populations.